WO2020237836A1 - Preparation method for 4-idarubicin hydrochloride - Google Patents

Preparation method for 4-idarubicin hydrochloride Download PDF

Info

Publication number
WO2020237836A1
WO2020237836A1 PCT/CN2019/100198 CN2019100198W WO2020237836A1 WO 2020237836 A1 WO2020237836 A1 WO 2020237836A1 CN 2019100198 W CN2019100198 W CN 2019100198W WO 2020237836 A1 WO2020237836 A1 WO 2020237836A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
compound
reaction
molecular sieve
batches
Prior art date
Application number
PCT/CN2019/100198
Other languages
French (fr)
Chinese (zh)
Inventor
苏进财
代清宇
吴舰
王华萍
柴雨柱
徐丹
朱春霞
田舟山
Original Assignee
南京正大天晴制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京正大天晴制药有限公司 filed Critical 南京正大天晴制药有限公司
Publication of WO2020237836A1 publication Critical patent/WO2020237836A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • C07H15/252Naphthacene radicals, e.g. daunomycins, adriamycins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Definitions

  • the invention relates to the field of medicinal chemistry, in particular to a preparation method of 4-demethoxydaunorubicin hydrochloride.
  • Anthracycline compounds are a class of substances widely used in the treatment of hematological malignancies and solid tumors, among which (7S,9S)-9-acetyl-7,8,9,10-tetrahydro-6,7,9, 11-tetrahydroxy-7-O-(2,3,6-tideoxy-3-amino- ⁇ -L-lyxo-hex-pyranose)-5,12-tetraphenyl hydrochloride, namely 4 -Demethoxydaunorubicin is a first-line drug for the treatment of relapsed and refractory adult acute myeloid leukemia (AML). It was developed and produced by Pharmacia Pretron and was approved by the FDA on September 27, 1990. Approved by CFDA in 2004 for listing. Compared with daunorubicin hydrochloride, 4-demethoxydaunorubicin has the advantages of less side effects, better curative effect, and lower drug resistance.
  • the present invention aims to provide an improved (7S,9S)-9-acetyl-7,8,9,10-tetrahydro-6,7,9,11-tetrahydroxy-7-O suitable for scale-up production -(2,3,6-Tideoxy-3-amino- ⁇ -L-lyxo-hex-pyranose)-5,12-Phenyltetraphenyl hydrochloride synthesis method.
  • the present invention provides a method for preparing a compound of formula C, the route is as follows:
  • Compound B is reacted in the presence of anhydrous MgX 2 , YI and tetrabutylammonium halide to obtain compound C, wherein R 1 is selected from C1-C3 alkyl, X is halogen, and Y is alkali metal.
  • the compound B: MgX 2 : YI: tetrabutylammonium halide 1:1 ⁇ 3:0.5 ⁇ 2:0.1 ⁇ 2 is charged in a molar ratio for reaction; preferably, it is in molar ratio
  • X is selected from Cl, Br, or I; preferably Cl.
  • Y is selected from Na or K; preferably K.
  • the tetrabutylammonium halide is selected from one or a mixture of two or more of tetrabutylammonium chloride, tetrabutylammonium bromide or tetrabutylammonium iodide; preferably tetrabutylammonium iodide Ammonium.
  • R 1 is methyl, ethyl, n-propyl or isopropyl; preferably methyl.
  • the reaction solvent is tetrahydrofuran, dioxane or ethylene glycol dimethyl ether; preferably tetrahydrofuran.
  • the above reaction temperature is 35-75°C; preferably 50-75°C; more preferably 50-60°C.
  • the reaction time of the above reaction is 6 to 48 hours; preferably 10 to 36 hours, more preferably 12 to 24 hours.
  • the above reaction process is carried out under water-controlled conditions; preferably, the water content of the reaction system is controlled within 3%; more preferably, the water content of the reaction system is controlled within 1%.
  • nitrogen gas and/or molecular sieves are added to control moisture.
  • the molecular screen is selected from or Molecular sieve; preferably Molecular sieve.
  • the amount of molecular sieve added is 0.2 to 1 times that of Compound B by mass; preferably 0.3 to 0.8 times; more preferably 0.4 to 0.6 times; most preferably 0.5 times.
  • the MgX 2 , YI and tetrabutylammonium halide are added to the reaction vessel by batch feeding.
  • the solvent, compound B, and optional molecular sieve are added to the reaction vessel in the first batch of the above reaction; the second to the last batch is put into the pre-packed mixture of MgX 2 , YI and tetrabutylammonium halide
  • the batches are fed in batches of 3-10 batches; more preferably, the batches are fed in 4-8 batches; more preferably, the batches are fed in 4-7 batches; most preferably, the batches are fed in 6 batches.
  • the present invention provides a method for preparing compound C, the route is as follows:
  • the reaction is carried out in the amount of feeding; in terms of mass ratio, the molecular sieve is 0.5 times that of compound B; the reaction temperature is 50-60°C; the reaction time is 11-15h; the reaction is carried out by batch feeding.
  • the present invention provides a method for preparing compound D according to the following reaction route:
  • the present invention provides a preparation method of compound E, which is carried out according to the following reaction route:
  • the present invention provides a method for preparing compound F, which is carried out according to the following reaction route:
  • the present invention provides a method for preparing compound B, wherein R 1 is a methyl group, and proceed according to the following reaction route:
  • the new preparation method provided by the present invention can reduce the amount of salt used in the reaction system, reduce the impact of reduced yield due to reaction amplification, and inhibit the increase of impurity I and impurity II during the reaction process, and has great advantages in production practice .
  • C1-C3 alkyl includes C1 alkyl, C2 alkyl, and C3 alkyl. Examples include but are not limited to methyl, ethyl, n-propyl, and isopropyl.
  • TBAI refers to tetrabutylammonium iodide.
  • K refers to potassium
  • I means iodine.
  • Me refers to methyl
  • Compound C refers to a compound with a molecular structure of Formula C, rather than elemental carbon.
  • Analytical method According to high performance liquid chromatography (Chinese Pharmacopoeia 2015 Edition Four General Rules 0512), use octadecyl silane bonded silica as filler [Welch Ultimate AQ-C18 (4.6mm ⁇ 250mm, 5 ⁇ m) or equivalent chromatogram Column]; Using 0.1% phosphoric acid solution as mobile phase A and methanol as mobile phase B, perform linear gradient elution according to the following table; flow rate is 1.0 ml per minute; column temperature is 35°C; detection wavelength is 254 nm. Accurately measure 20 ⁇ l of the test solution, inject it into the liquid chromatograph, record the chromatogram, and calculate the content of compound B, compound C, impurity I and impurity II by area normalization.
  • the molecular sieve is crushed, it is put into a crucible, placed in a muffle furnace and heated to 400°C ⁇ 10°C for 2 hours, cooled to 100°C ⁇ 10°C for 1 hour, then transferred to a large airtight dry container filled with nitrogen for storage, and cooled More than 3h.
  • W/W is expressed as the mass ratio of molecular sieve to compound B; unknown impurities are not listed.
  • R 1 Me, about 3.53 mol, calculated as 1 eq
  • compound C (2.5mol, counted as 1eq), trifluoromethanesulfonic anhydride (1eq), N,N-diisopropylethylamine (3eq) and 4-dimethylaminopyridine (0.5eq)
  • pyridine solution Put into the pyridine solution, carry out the reaction, after the reaction is finished, separate and purify by the silica gel column, obtain compound D.
  • compound D (2.5mol, calculated as 1eq), palladium acetate (0.1eq), 1,1'-bis(diphenylphosphine)ferrocene (0.1eq), N-ethyl diiso Propylamine (2eq) and formic acid (2eq) were added to the solvent dioxane and reacted at 40-60°C. After the reaction was completed, compound E was obtained.
  • reaction formula add 1.0M sodium hydroxide aqueous solution, stir at room temperature for 1 h, adjust the pH of the hydrochloric acid aqueous solution to 3-4, perform salting and crystallization, and then suction filtration and drying to obtain compound F with a purity of >98%.
  • reaction results were detected by HPLC, and the area normalization method was used to calculate the content of products and impurities. The results are shown in the following table.

Abstract

Provided is a method for preparing 4-idarubicin hydrochloride. The method comprises the step of preparing compound B into compound C in the presence of tetrabutyl ammonium halide, and the 4-idarubicin hydrochloride can be further obtained. The preparation method can reduce the usage amount of a salt in a reaction system, and also reduce the effect of yield reduction due to reaction amplification, inhibit the increase of impurity I and impurity II during the reaction process, and has great advantages in production practice.

Description

4-脱甲氧柔红霉素盐酸盐的制备方法Preparation method of 4-demethoxydaunorubicin hydrochloride
本申请要求申请号为201910466305.4、申请日为2019.5.31的中国专利申请的优先权。This application claims the priority of the Chinese patent application whose application number is 201910466305.4 and the application date is 2019.5.31.
技术领域Technical field
本发明涉及药物化学领域,具体为一种4-脱甲氧柔红霉素盐酸盐的制备方法。The invention relates to the field of medicinal chemistry, in particular to a preparation method of 4-demethoxydaunorubicin hydrochloride.
背景技术Background technique
蒽环类化合物是一类广泛应用于治疗血液系统恶性肿瘤和实体肿瘤的物质,其中(7S,9S)-9-乙酰基-7,8,9,10-四氢-6,7,9,11-四羟-7-O-(2,3,6-三脱氧-3-氨基-α-L-来苏-已-吡喃糖)-5,12-骈四苯盐酸盐,即4-脱甲氧柔红霉素是治疗复发性和难治性的成人急性髓细胞白血病(AML)的一线用药,由法玛西亚普强公司开发生产,1990年09月27日经FDA批准上市,2004年由CFDA批准上市。相较于盐酸柔红霉素,4-脱甲氧柔红霉素具有毒副作用较小、疗效较好、耐药性较低等优点。Anthracycline compounds are a class of substances widely used in the treatment of hematological malignancies and solid tumors, among which (7S,9S)-9-acetyl-7,8,9,10-tetrahydro-6,7,9, 11-tetrahydroxy-7-O-(2,3,6-tideoxy-3-amino-α-L-lyxo-hex-pyranose)-5,12-tetraphenyl hydrochloride, namely 4 -Demethoxydaunorubicin is a first-line drug for the treatment of relapsed and refractory adult acute myeloid leukemia (AML). It was developed and produced by Pharmacia Pretron and was approved by the FDA on September 27, 1990. Approved by CFDA in 2004 for listing. Compared with daunorubicin hydrochloride, 4-demethoxydaunorubicin has the advantages of less side effects, better curative effect, and lower drug resistance.
发明内容Summary of the invention
本发明旨在提供一种改进的、适合放大生产的(7S,9S)-9-乙酰基-7,8,9,10-四氢-6,7,9,11-四羟-7-O-(2,3,6-三脱氧-3-氨基-α-L-来苏-已-吡喃糖)-5,12-骈四苯盐酸盐的合成方法。The present invention aims to provide an improved (7S,9S)-9-acetyl-7,8,9,10-tetrahydro-6,7,9,11-tetrahydroxy-7-O suitable for scale-up production -(2,3,6-Tideoxy-3-amino-α-L-lyxo-hex-pyranose)-5,12-Phenyltetraphenyl hydrochloride synthesis method.
一方面,本发明提供了一种式C化合物的制备方法,路线如下:In one aspect, the present invention provides a method for preparing a compound of formula C, the route is as follows:
Figure PCTCN2019100198-appb-000001
Figure PCTCN2019100198-appb-000001
化合物B在无水MgX 2、YI和四丁基卤化铵存在的条件下,反应得到化合物C,其中R 1选自C1-C3的烷基,X为卤素,Y为碱金属。 Compound B is reacted in the presence of anhydrous MgX 2 , YI and tetrabutylammonium halide to obtain compound C, wherein R 1 is selected from C1-C3 alkyl, X is halogen, and Y is alkali metal.
在一些实施方案中,以摩尔比计,按照化合物B:MgX 2:YI:四丁基卤化铵=1:1~3:0.5~2:0.1~2的量投料进行反应;优选的,以摩尔比计,按照化合物B:MgX 2:YI:四丁基卤化铵=1:1.5~2:1~2:0.3~1或者1:1.5~2:1~2:0.1~2的量投料进行反应;更优选的,以摩尔比计,按照化合物B:MgX 2:YI:四丁基卤化铵=1:1.7:1.6:0.5的量投料进行反应。 In some embodiments, the compound B: MgX 2 : YI: tetrabutylammonium halide = 1:1~3:0.5~2:0.1~2 is charged in a molar ratio for reaction; preferably, it is in molar ratio The ratio is calculated according to the compound B: MgX 2 : YI: tetrabutylammonium halide=1:1.5~2:1~2:0.3~1 or 1:1.5~2:1~2:0.1~2 for reaction ; More preferably, based on the molar ratio, the compound B: MgX 2 : YI: tetrabutylammonium halide=1:1.7:1.6:0.5 is charged for the reaction.
在一些实施方案中,X选自Cl、Br或I;优选为Cl。In some embodiments, X is selected from Cl, Br, or I; preferably Cl.
在一些实施方案中,Y选自Na或K;优选为K。In some embodiments, Y is selected from Na or K; preferably K.
在一些实施方案中,四丁基卤化铵选自四丁基氯化铵、四丁基溴化铵或四丁基碘化铵中的一种或两种以上混合物;优选为四丁基碘化铵。In some embodiments, the tetrabutylammonium halide is selected from one or a mixture of two or more of tetrabutylammonium chloride, tetrabutylammonium bromide or tetrabutylammonium iodide; preferably tetrabutylammonium iodide Ammonium.
在一些实施方案中,R 1为甲基、乙基、正丙基或异丙基;优选为甲基。 In some embodiments, R 1 is methyl, ethyl, n-propyl or isopropyl; preferably methyl.
在一些实施方案中,反应溶剂为四氢呋喃、二氧六环或乙二醇二甲醚;优选为四氢呋喃。In some embodiments, the reaction solvent is tetrahydrofuran, dioxane or ethylene glycol dimethyl ether; preferably tetrahydrofuran.
在一些实施方案中,上述反应温度为35~75℃;优选为50~75℃;更优选为50~60℃。In some embodiments, the above reaction temperature is 35-75°C; preferably 50-75°C; more preferably 50-60°C.
在一些实施方案中,上述反应的反应时间为6~48h;优选为10~36h,更优选为12~24h。In some embodiments, the reaction time of the above reaction is 6 to 48 hours; preferably 10 to 36 hours, more preferably 12 to 24 hours.
在一些实施方案中,上述反应过程在控制水的条件下进行;优选的,反应体系的水分控制在3%以内;更优选的,反应体系的水分控制在1%以内。In some embodiments, the above reaction process is carried out under water-controlled conditions; preferably, the water content of the reaction system is controlled within 3%; more preferably, the water content of the reaction system is controlled within 1%.
在一些实施方案中,采用通入氮气和/或加入分子筛方法控制水分。In some embodiments, nitrogen gas and/or molecular sieves are added to control moisture.
在一些实施方案中,所述分子筛选自
Figure PCTCN2019100198-appb-000002
Figure PCTCN2019100198-appb-000003
分子筛;优选为
Figure PCTCN2019100198-appb-000004
分子筛。
In some embodiments, the molecular screen is selected from
Figure PCTCN2019100198-appb-000002
or
Figure PCTCN2019100198-appb-000003
Molecular sieve; preferably
Figure PCTCN2019100198-appb-000004
Molecular sieve.
在一些实施方案中,加入分子筛的量,以质量计,为化合物B的0.2~1倍;优选为0.3~0.8倍;更优选为0.4~0.6倍;最优选为0.5倍。In some embodiments, the amount of molecular sieve added is 0.2 to 1 times that of Compound B by mass; preferably 0.3 to 0.8 times; more preferably 0.4 to 0.6 times; most preferably 0.5 times.
在一些实施方案中,所述MgX 2、YI和四丁基卤化铵采用分批投料的方式加入反应容器。 In some embodiments, the MgX 2 , YI and tetrabutylammonium halide are added to the reaction vessel by batch feeding.
在一些实施方案中,上述反应第一批在反应容器中加入溶剂、化合物B和任选的分子筛;第二批至最后一批投入预分装的MgX 2、YI和四丁基卤化铵的混合物;优选的,分批投料的批次为3~10批;进一步优选为分4~8批投料;更优选为分4~7批投料;最优选为分6批投料。 In some embodiments, the solvent, compound B, and optional molecular sieve are added to the reaction vessel in the first batch of the above reaction; the second to the last batch is put into the pre-packed mixture of MgX 2 , YI and tetrabutylammonium halide Preferably, the batches are fed in batches of 3-10 batches; more preferably, the batches are fed in 4-8 batches; more preferably, the batches are fed in 4-7 batches; most preferably, the batches are fed in 6 batches.
在一些实施方案中,本发明提供了一种化合物C的制备方法,路线如下:In some embodiments, the present invention provides a method for preparing compound C, the route is as follows:
Figure PCTCN2019100198-appb-000005
Figure PCTCN2019100198-appb-000005
其中,化合物B在MgCl 2、KI、TBAI和分子筛存在的条件下,加热反应,得到化合物C,其中,以摩尔比计,按照化合物B:MgCl 2:KI:TBAI=1:1.7:1.6:0.5的量投料进行反应;以质量比计,分子筛为化合物B的0.5倍;反应温度为50~60℃;反应时间为11~15h;该反应采用分批投料的方式进行。 Wherein, compound B is heated and reacted in the presence of MgCl 2 , KI, TBAI and molecular sieves to obtain compound C, wherein, in molar ratio, according to compound B: MgCl 2 : KI: TBAI=1:1.7:1.6:0.5 The reaction is carried out in the amount of feeding; in terms of mass ratio, the molecular sieve is 0.5 times that of compound B; the reaction temperature is 50-60°C; the reaction time is 11-15h; the reaction is carried out by batch feeding.
另一方面,本发明提供了一种化合物D的制备方法,按照如下反应路线进行:On the other hand, the present invention provides a method for preparing compound D according to the following reaction route:
Figure PCTCN2019100198-appb-000006
Figure PCTCN2019100198-appb-000006
另一方面,本发明提供了化合物E的制备方法,按照如下反应路线进行:On the other hand, the present invention provides a preparation method of compound E, which is carried out according to the following reaction route:
Figure PCTCN2019100198-appb-000007
Figure PCTCN2019100198-appb-000007
另一方面,本发明提供了化合物F的制备方法,按照如下反应路线进行:On the other hand, the present invention provides a method for preparing compound F, which is carried out according to the following reaction route:
Figure PCTCN2019100198-appb-000008
Figure PCTCN2019100198-appb-000008
另一方面,本发明提供了化合物B的制备方法,其中R 1为甲基,按照如下反应路线进行: On the other hand, the present invention provides a method for preparing compound B, wherein R 1 is a methyl group, and proceed according to the following reaction route:
Figure PCTCN2019100198-appb-000009
Figure PCTCN2019100198-appb-000009
本发明提供的新的制备方法能够降低反应体系中盐的使用量,降低由于反应放大导致的收率降低等影响,抑制反应过程中杂质I和杂质II的增加,在生产实践中具有较大优势。The new preparation method provided by the present invention can reduce the amount of salt used in the reaction system, reduce the impact of reduced yield due to reaction amplification, and inhibit the increase of impurity I and impurity II during the reaction process, and has great advantages in production practice .
本发明所述的术语或符号定义如下:The terms or symbols in the present invention are defined as follows:
术语“C1~C3烷基”包括C1烷基、C2烷基、C3烷基,实例包括但不限于甲基、乙基、正丙基、异丙基。The term "C1-C3 alkyl" includes C1 alkyl, C2 alkyl, and C3 alkyl. Examples include but are not limited to methyl, ethyl, n-propyl, and isopropyl.
TBAI是指四丁基碘化铵。TBAI refers to tetrabutylammonium iodide.
K是指钾。K refers to potassium.
I是指碘。I means iodine.
h是指小时。h means hour.
eq是指当量。eq means equivalent.
Me是指甲基。Me refers to methyl.
化合物C指分子结构如式C的化合物,而非单质碳。Compound C refers to a compound with a molecular structure of Formula C, rather than elemental carbon.
杂质I结构式为:
Figure PCTCN2019100198-appb-000010
The structural formula of impurity I is:
Figure PCTCN2019100198-appb-000010
杂质II结构式为:
Figure PCTCN2019100198-appb-000011
The structural formula of impurity II is:
Figure PCTCN2019100198-appb-000011
具体实施方案Specific implementation plan
为了便于所属领域技术人员理解本发明,以下通过具体实施例对本发明的合成路线做具体说明:In order to facilitate those skilled in the art to understand the present invention, the following specific examples illustrate the synthetic route of the present invention:
分析方法:按照高效液相色谱法(中国药典2015版四部通则0512),用十八烷基硅烷键合硅胶为填充剂[Welch Ultimate AQ-C18(4.6mm×250mm,5μm)或效能相当的色谱柱];以0.1%磷酸溶液为流动相A,甲醇为流动相B,按下表进行线性梯度洗脱;流速为每分钟1.0ml;柱温为35℃;检测波长为254nm。精密量取供试品溶液20μl,注入液相色谱仪,记录色谱图,面积归一化法计算化合物B、化合物C、杂质I和杂质II的含量。Analytical method: According to high performance liquid chromatography (Chinese Pharmacopoeia 2015 Edition Four General Rules 0512), use octadecyl silane bonded silica as filler [Welch Ultimate AQ-C18 (4.6mm×250mm, 5μm) or equivalent chromatogram Column]; Using 0.1% phosphoric acid solution as mobile phase A and methanol as mobile phase B, perform linear gradient elution according to the following table; flow rate is 1.0 ml per minute; column temperature is 35°C; detection wavelength is 254 nm. Accurately measure 20μl of the test solution, inject it into the liquid chromatograph, record the chromatogram, and calculate the content of compound B, compound C, impurity I and impurity II by area normalization.
Figure PCTCN2019100198-appb-000012
Figure PCTCN2019100198-appb-000012
实施例1 MgCl 2、KI和TBAI对反应的影响 Example 1 The influence of MgCl 2 , KI and TBAI on the reaction
按照如下反应式,将四氢呋喃、2.2kg化合物B(R 1=Me,约3.53mol,计为1eq)加入至反应釜中,搅拌(150r/min~250r/min),按表1所示的投料比一次性加入无水氯化镁、碘化 钾和四丁基碘化铵,抽真空氮气置换,室温搅拌0.5h,开启加热循环系统,控制反应温度为40±3℃,反应7h,即得到化合物C以及杂质I和杂质II。 According to the following reaction formula, add tetrahydrofuran and 2.2 kg of compound B (R 1 =Me, about 3.53 mol, counted as 1 eq) into the reactor, stir (150r/min~250r/min), according to the charging shown in Table 1. Add anhydrous magnesium chloride, potassium iodide and tetrabutylammonium iodide at one time, vacuum and nitrogen replacement, stir at room temperature for 0.5h, turn on the heating circulation system, control the reaction temperature to 40±3℃, react for 7h, then get compound C and impurities I and impurities II.
Figure PCTCN2019100198-appb-000013
Figure PCTCN2019100198-appb-000013
HPLC检测反应结果,面积归一化法计算产物及杂质的含量,结果见表1。The reaction results were detected by HPLC, and the area normalization method was used to calculate the content of products and impurities. The results are shown in Table 1.
表1Table 1
Figure PCTCN2019100198-appb-000014
Figure PCTCN2019100198-appb-000014
注:未知杂质未列出。Note: Unknown impurities are not listed.
化合物C:[M+Na] +632.0;[M-H] -608.1; Compound C: [M + Na] + 632.0; [MH] - 608.1;
化合物C  1H-NMR(500MHz,DMSO-d 6)ppmδ:1.152~1.165(3H,d),1.509~1.541(1H,m),2.053~2.119(2H,m),2.215~2.243(1H,d),2.293(3H,s),2.920(2H,s),3.535(1H,s),4.052~4.078(1H,m),4.230~4.268(1H,m),4.878(1H,s),4.960(1H,s),5.237(1H,s),5.492(1H,s),7.300~7.316(1H,d),7.655~7.670(1H,d),7.746~7.778(1H,t),9.005~9.019(1H,d),11.869(1H,s),12.717(1H,s),13.313(1H,s)。 Compound C 1 H-NMR (500MHz, DMSO-d 6 ) ppmδ: 1.152~1.165 (3H, d), 1.509~1.541 (1H, m), 2.053~2.119 (2H, m), 2.215~2.243 (1H, d) ), 2.293(3H,s), 2.920(2H,s), 3.535(1H,s), 4.052~4.078(1H,m), 4.230~4.268(1H,m), 4.878(1H,s), 4.960( 1H, s), 5.237 (1H, s), 5.492 (1H, s), 7.300 ~ 7.316 (1H, d), 7.655 ~ 7.670 (1H, d), 7.746 ~ 7.778 (1H, t), 9.005 ~ 9.019 ( 1H, d), 11.869 (1H, s), 12.717 (1H, s), 13.313 (1H, s).
实施例2 温度对反应的影响Example 2 The influence of temperature on the reaction
按照实施例1所述方法,将四氢呋喃、2.2kg化合物B(R 1=Me,约3.53mol,计为1eq)加入至反应釜中,搅拌(150r/min~250r/min),按表2所示的投料比一次性加入无水氯化镁、碘化钾和四丁基碘化铵,抽真空氮气置换,室温搅拌0.5h,开启加热循环系统,按照表2所示控制反应温度,反应7h时间后,反应结束,HPLC检测反应结果,面积归一化法计算产物及杂质的含量,结果见表2。 According to the method described in Example 1, tetrahydrofuran and 2.2 kg of compound B (R 1 =Me, about 3.53 mol, calculated as 1 eq) were added to the reaction kettle, stirred (150r/min~250r/min), according to Table 2 Add anhydrous magnesium chloride, potassium iodide and tetrabutylammonium iodide at one time to the feeding ratio shown, vacuum nitrogen replacement, stir at room temperature for 0.5h, turn on the heating circulation system, control the reaction temperature according to Table 2, and react for 7h. At the end, the reaction result was detected by HPLC, and the area normalization method was used to calculate the content of the product and impurities.
表2Table 2
Figure PCTCN2019100198-appb-000015
Figure PCTCN2019100198-appb-000015
Figure PCTCN2019100198-appb-000016
Figure PCTCN2019100198-appb-000016
注:未知杂质未列出。Note: Unknown impurities are not listed.
实施例3 分子筛对反应的影响Example 3 The influence of molecular sieve on the reaction
Figure PCTCN2019100198-appb-000017
分子筛粉碎后装入坩埚中,放置于马弗炉中加热至400℃±10℃烘2小时,降温至100℃±10℃烘1小时后,转移至充满氮气大的密闭干燥容器中保存,降温3h以上。
will
Figure PCTCN2019100198-appb-000017
After the molecular sieve is crushed, it is put into a crucible, placed in a muffle furnace and heated to 400℃±10℃ for 2 hours, cooled to 100℃±10℃ for 1 hour, then transferred to a large airtight dry container filled with nitrogen for storage, and cooled More than 3h.
按照实施例1所述方法,将四氢呋喃、2.2kg化合物B(R 1=Me,约3.53mol,计为1eq)加入至反应釜中,搅拌(150r/min~250r/min),按表3所示的投料比一次性加入活化后的分子筛、无水氯化镁、碘化钾、四丁基碘化铵,抽真空氮气置换,室温搅拌0.5h,开启加热循环系统,控制反应温度为50~60℃,反应7h时间后,反应结束,HPLC检测反应结果,面积归一化法计算产物及杂质的含量,结果见表3 According to the method described in Example 1, tetrahydrofuran and 2.2 kg of compound B (R 1 =Me, about 3.53 mol, calculated as 1 eq) were added to the reaction kettle, stirred (150r/min~250r/min), according to Table 3 The charging ratio shown is one-time addition of activated molecular sieve, anhydrous magnesium chloride, potassium iodide, and tetrabutylammonium iodide, vacuum nitrogen replacement, stirring at room temperature for 0.5h, turning on the heating circulation system, and controlling the reaction temperature to 50-60°C. After 7h, the reaction is over, HPLC detects the reaction result, and the area normalization method calculates the content of product and impurities. The results are shown in Table 3.
表3table 3
Figure PCTCN2019100198-appb-000018
Figure PCTCN2019100198-appb-000018
注:W/W表示为分子筛与化合物B的质量比;未知杂质未列出。Note: W/W is expressed as the mass ratio of molecular sieve to compound B; unknown impurities are not listed.
在编号3-1至编号3-4的反应中,发明人观察到当分子筛投入量增大后,并不能显著改善化合物C的生成量,反而会使整个反应体系随着分子筛投入量的增加变得更加黏稠,影响后续操作。In the reactions No. 3-1 to No. 3-4, the inventors observed that when the amount of molecular sieve input was increased, the amount of compound C produced could not be significantly improved, but the entire reaction system would change with the increase of the amount of molecular sieve input. Make it more viscous, affecting subsequent operations.
实施例4 分批加料方式对反应的影响Example 4 The effect of batch feeding method on the reaction
按照实施例1所述方法,将四氢呋喃、2.2kg化合物B(R 1=Me,约3.53mol,计为1eq)加入至反应釜中,搅拌(150r/min~250r/min),加入1.1kg活化后的分子筛,再按表4所示的投料比加入预选分装的无水氯化镁、碘化钾和四丁基碘化铵混合物,每次投料后,抽真空氮气置换,开启加热循环系统,控制反应温度为50~60℃,反应时间如表4,反应结束后,HPLC 检测反应结果,面积归一化法计算各产物及杂质的含量,结果见表4。 According to the method described in Example 1, add tetrahydrofuran and 2.2 kg of compound B (R 1 =Me, about 3.53 mol, calculated as 1 eq) into the reaction kettle, stir (150r/min~250r/min), add 1.1kg to activate After the molecular sieve, add the pre-selected mixture of anhydrous magnesium chloride, potassium iodide and tetrabutylammonium iodide according to the feeding ratio shown in Table 4. After each feeding, vacuum nitrogen replacement, open the heating circulation system, and control the reaction temperature The reaction time is 50-60°C, and the reaction time is as shown in Table 4. After the reaction is completed, HPLC detects the reaction result, and the area normalization method calculates the content of each product and impurities.
表4Table 4
Figure PCTCN2019100198-appb-000019
Figure PCTCN2019100198-appb-000019
注:“+”表示补加;未知杂质未列出。Note: "+" means supplement; unknown impurities are not listed.
实施例5 化合物D的制备Example 5 Preparation of Compound D
按照如下反应式,将化合物C(2.5mol,计为1eq)、三氟甲磺酸酐(1eq)、N,N-二异丙基乙胺(3eq)和4-二甲氨基吡啶(0.5eq)投入吡啶溶液中,进行反应,反应结束后,经硅胶柱分离纯化,即得化合物D。According to the following reaction formula, compound C (2.5mol, counted as 1eq), trifluoromethanesulfonic anhydride (1eq), N,N-diisopropylethylamine (3eq) and 4-dimethylaminopyridine (0.5eq) Put into the pyridine solution, carry out the reaction, after the reaction is finished, separate and purify by the silica gel column, obtain compound D.
Figure PCTCN2019100198-appb-000020
Figure PCTCN2019100198-appb-000020
实施例6 化合物E的制备Example 6 Preparation of Compound E
按照如下反应式,将化合物D(2.5mol,计为1eq)、醋酸钯(0.1eq)、1,1'-双(二苯基膦)二茂铁(0.1eq)、N-乙基二异丙胺(2eq)和甲酸(2eq)加入到溶剂二氧六环中,40~60℃反应,待反应结束后得到化合物E。According to the following reaction formula, compound D (2.5mol, calculated as 1eq), palladium acetate (0.1eq), 1,1'-bis(diphenylphosphine)ferrocene (0.1eq), N-ethyl diiso Propylamine (2eq) and formic acid (2eq) were added to the solvent dioxane and reacted at 40-60°C. After the reaction was completed, compound E was obtained.
Figure PCTCN2019100198-appb-000021
Figure PCTCN2019100198-appb-000021
实施例7 化合物F的制备Example 7 Preparation of Compound F
按照如下反应式,加入1.0M氢氧化钠水溶液,室温下搅拌1h,盐酸水溶液调解pH至3~4,进行成盐析晶,抽滤干燥后,即得纯度>98%的化合物F。According to the following reaction formula, add 1.0M sodium hydroxide aqueous solution, stir at room temperature for 1 h, adjust the pH of the hydrochloric acid aqueous solution to 3-4, perform salting and crystallization, and then suction filtration and drying to obtain compound F with a purity of >98%.
Figure PCTCN2019100198-appb-000022
Figure PCTCN2019100198-appb-000022
实施例8 化合物B(R 1=Me)的制备 Example 8 Preparation of Compound B (R 1 =Me)
按照如下反应式,以二氯甲烷/甲醇和混合溶液作为反应溶剂,将化合物A(3.5mol,记为1eq)、N-乙基二异丙胺(5eq)和CF 3COOEt(4eq),30~40℃条件下搅拌5小时,即得化合物B(R 1=Me)。 According to the following reaction formula, using dichloromethane/methanol and a mixed solution as the reaction solvent, compound A (3.5mol, recorded as 1eq), N-ethyldiisopropylamine (5eq) and CF 3 COOEt (4eq), 30~ Stir at 40°C for 5 hours to obtain compound B (R 1 =Me).
Figure PCTCN2019100198-appb-000023
Figure PCTCN2019100198-appb-000023
对比例1Comparative example 1
将2.2kg的化合物B(R 1=Me)溶解在4.95L的四氢呋喃中。将2.75kg的无水氯化镁和2.2kg的无水碘化钾加入到与大气中水分不相接触的环境中。混合物在40℃下反应至7h,即得化合物C以及杂质I和杂质II。 2.2 kg of compound B (R 1 =Me) was dissolved in 4.95 L of tetrahydrofuran. Add 2.75 kg of anhydrous magnesium chloride and 2.2 kg of anhydrous potassium iodide to an environment that is not in contact with atmospheric moisture. The mixture is reacted at 40°C for 7 hours to obtain compound C, impurity I and impurity II.
HPLC检测反应结果,面积归一化法计算产物及杂质的含量,结果见下表。The reaction results were detected by HPLC, and the area normalization method was used to calculate the content of products and impurities. The results are shown in the following table.
化合物BCompound B 化合物CCompound C 杂质IImpurity I 杂质IIImpurity II
13.92%13.92% 17.71%17.71% 16.43%16.43% 44.35%44.35%
注:未知杂质未列出。Note: Unknown impurities are not listed.

Claims (40)

  1. 一种式C化合物的制备方法,路线如下:A method for preparing a compound of formula C, the route is as follows:
    Figure PCTCN2019100198-appb-100001
    Figure PCTCN2019100198-appb-100001
    其中,化合物B在无水MgX 2、YI和四丁基卤化铵存在的条件下,反应得到化合物C,其中R 1选自C1-C3的烷基,X为卤素,Y为碱金属。 Wherein, compound B is reacted in the presence of anhydrous MgX 2 , YI and tetrabutylammonium halide to obtain compound C, wherein R 1 is selected from C1-C3 alkyl, X is halogen, and Y is alkali metal.
  2. 如权利要求1所述的制备方法,X选自Cl、Br或I。The preparation method according to claim 1, wherein X is selected from Cl, Br or I.
  3. 如权利要求2所述的制备方法,X为Cl。The preparation method according to claim 2, wherein X is Cl.
  4. 如权利要求1所述的制备方法,Y选自Na或K。The preparation method according to claim 1, wherein Y is selected from Na or K.
  5. 如权利要求4所述的制备方法,Y为K。The preparation method according to claim 4, Y is K.
  6. 如权利要求1所述的制备方法,四丁基卤化铵选自四丁基氯化铵、四丁基溴化铵或四丁基碘化铵中的一种或两种以上混合物。The preparation method according to claim 1, wherein the tetrabutylammonium halide is selected from one or a mixture of two or more of tetrabutylammonium chloride, tetrabutylammonium bromide or tetrabutylammonium iodide.
  7. 如权利要求6所述的制备方法,四丁基卤化铵为四丁基碘化铵。The preparation method according to claim 6, wherein the tetrabutylammonium halide is tetrabutylammonium iodide.
  8. 如权利要求1所述的制备方法,R 1为甲基、乙基、正丙基或异丙基。 The preparation method according to claim 1, wherein R 1 is methyl, ethyl, n-propyl or isopropyl.
  9. 如权利要求8所述的制备方法,R 1为甲基。 The preparation method according to claim 8, wherein R 1 is a methyl group.
  10. 如权利要求1所述的制备方法,以摩尔比计,按照化合物B:MgX 2:YI:四丁基卤化铵=1:1~3:0.5~2:0.1~2的量投料进行反应。 The preparation method according to claim 1, wherein the compound B: MgX 2 : YI: tetrabutylammonium halide=1:1~3:0.5~2:0.1~2 are charged and reacted in molar ratio.
  11. 如权利要求10所述的制备方法,以摩尔比计,按照化合物B:MgX 2:YI:四丁基卤化铵=1:1.5~2:1~2:0.3~1的量投料进行反应。 The preparation method according to claim 10, based on the molar ratio, the compound B: MgX 2 : YI: tetrabutylammonium halide=1:1.5-2:1-2:0.3-1 is charged and reacted.
  12. 如权利要求11所述的制备方法,以摩尔比计,按照化合物B:MgX 2:YI:四丁基卤化铵=1:1.7:1.6:0.5的量投料进行反应。 The preparation method according to claim 11, based on the molar ratio, the compound B: MgX 2 : YI: tetrabutylammonium halide=1:1.7:1.6:0.5 is charged and reacted.
  13. 如权利要求1所述的制备方法,反应溶剂为四氢呋喃、二氧六环或乙二醇二甲醚。The preparation method according to claim 1, wherein the reaction solvent is tetrahydrofuran, dioxane or ethylene glycol dimethyl ether.
  14. 如权利要求13所述的制备方法,反应溶剂为四氢呋喃。The preparation method according to claim 13, wherein the reaction solvent is tetrahydrofuran.
  15. 如权利要求1所述的制备方法,反应温度为35~75℃。The preparation method according to claim 1, wherein the reaction temperature is 35-75°C.
  16. 如权利要求15所述的制备方法,反应温度为50~75℃。The preparation method according to claim 15, wherein the reaction temperature is 50-75°C.
  17. 如权利要求16所述的制备方法,反应温度为50~60℃。The preparation method according to claim 16, wherein the reaction temperature is 50-60°C.
  18. 如权利要求1所述的制备方法,反应时间为6~48h。The preparation method according to claim 1, wherein the reaction time is 6 to 48 hours.
  19. 如权利要求18所述的制备方法,反应时间为10~36h。The preparation method according to claim 18, the reaction time is 10 to 36 hours.
  20. 如权利要求19所述的制备方法,反应时间为12~24h。The preparation method according to claim 19, the reaction time is 12-24h.
  21. 如权利要求1所述的制备方法,反应过程在控制水的条件下进行。The preparation method according to claim 1, wherein the reaction process is carried out under controlled water conditions.
  22. 如权利要求21所述的制备方法,反应体系的水分控制在3%以内。The preparation method according to claim 21, wherein the water content of the reaction system is controlled within 3%.
  23. 如权利要求22所述的制备方法,反应体系的水分控制在1%以内。The preparation method according to claim 22, wherein the water content of the reaction system is controlled within 1%.
  24. 如权利要求21-23任意一项所述的制备方法,通入氮气和/或加入分子筛方法控制水分。According to the preparation method according to any one of claims 21-23, nitrogen is introduced and/or molecular sieve is added to control moisture.
  25. 如权利要求24所述的制备方法,分子筛选自
    Figure PCTCN2019100198-appb-100002
    Figure PCTCN2019100198-appb-100003
    分子筛。
    The preparation method of claim 24, the molecular screening is from
    Figure PCTCN2019100198-appb-100002
    or
    Figure PCTCN2019100198-appb-100003
    Molecular sieve.
  26. 如权利要求25所述的制备方法,分子筛为
    Figure PCTCN2019100198-appb-100004
    分子筛。
    The preparation method of claim 25, wherein the molecular sieve is
    Figure PCTCN2019100198-appb-100004
    Molecular sieve.
  27. 如权利要求24所述的制备方法,加入分子筛的量,以质量计,为化合物B的0.2~1倍。The preparation method according to claim 24, wherein the amount of molecular sieve added is 0.2 to 1 times that of compound B by mass.
  28. 如权利要求27所述的制备方法,加入分子筛的量,以质量计,为化合物B的0.4~0.6倍。The preparation method according to claim 27, wherein the amount of molecular sieve added is 0.4 to 0.6 times that of compound B by mass.
  29. 如权利要求28所述的制备方法,加入分子筛的量,以质量计,为化合物B的0.5倍。The preparation method according to claim 28, wherein the amount of molecular sieve added is 0.5 times that of compound B by mass.
  30. 如权利要求1所述的制备方法,所述MgX 2、YI和四丁基卤化铵采用分批投料的方式加入反应容器。 The preparation method according to claim 1, wherein the MgX 2 , YI and tetrabutylammonium halide are fed into the reaction vessel in batches.
  31. 如权利要求30所述的制备方法,第一批在反应容器中加入溶剂、化合物B和任选的分子筛;第二批至最后一批投入预分装的MgX 2、YI和四丁基卤化铵的混合物。 The preparation method according to claim 30, the solvent, compound B and optional molecular sieve are added into the reaction vessel in the first batch; the pre-packed MgX 2 , YI and tetrabutylammonium halide are put into the second to the last batch mixture.
  32. 如权利要求30或31所述的制备方法,分批投料的批次为3~10批。The preparation method according to claim 30 or 31, wherein the batches of batch feeding are 3-10 batches.
  33. 如权利要求30或31所述的制备方法,分批投料的批次为4~8批。The preparation method according to claim 30 or 31, wherein the batches of batch feeding are 4-8 batches.
  34. 如权利要求30或31所述的制备方法,分批投料的批次为4~7批。The preparation method according to claim 30 or 31, the batches of batch feeding are 4-7 batches.
  35. 如权利要求30或31所述的制备方法,分批投料的批次为6批。The preparation method according to claim 30 or 31, wherein the batch of batch feeding is 6 batches.
  36. 一种化合物C的制备方法,路线如下:A preparation method of compound C, the route is as follows:
    Figure PCTCN2019100198-appb-100005
    Figure PCTCN2019100198-appb-100005
    其中,化合物B在MgCl 2、KI、TBAI和分子筛存在的条件下,加热反应,得到化合物C,其中,以摩尔比计,按照化合物B:MgCl 2:KI:TBAI=1:1.7:1.6:0.5的量投料进行反应;以质量比计,分子筛为化合物B的0.5倍;反应温度为50~60℃;反应时间为11~15h;该反应采用分批投料的方式进行。 Wherein, compound B is heated and reacted in the presence of MgCl 2 , KI, TBAI and molecular sieves to obtain compound C, wherein, in molar ratio, according to compound B: MgCl 2 : KI: TBAI=1:1.7:1.6:0.5 The reaction is carried out in the amount of feeding; in terms of mass ratio, the molecular sieve is 0.5 times that of compound B; the reaction temperature is 50-60°C; the reaction time is 11-15h; the reaction is carried out by batch feeding.
  37. 一种式D化合物的制备方法,先采用权利要求1-35任一项所述的制备方法或权利要求36所述的制备方法制得化合物C,再按照如下反应路线进一步得到化合物D:A method for preparing a compound of formula D, firstly using the preparation method of any one of claims 1-35 or the preparation method of claim 36 to obtain compound C, and then further obtain compound D according to the following reaction route:
    Figure PCTCN2019100198-appb-100006
    Figure PCTCN2019100198-appb-100006
  38. 一种式E化合物的制备方法,先采用权利要求37所述的制备方法制得化合物D,再按照如下反应路线进一步得到化合物E:A method for preparing a compound of formula E, firstly using the preparation method of claim 37 to obtain compound D, and then further obtaining compound E according to the following reaction route:
    Figure PCTCN2019100198-appb-100007
    Figure PCTCN2019100198-appb-100007
  39. 一种式F化合物的制备方法,先采用权利要求38所述的制备方法制得化合物E,再按照如下反应路线进一步得到化合物F:A method for preparing a compound of formula F, firstly adopting the preparation method of claim 38 to obtain compound E, and then further obtaining compound F according to the following reaction route:
    Figure PCTCN2019100198-appb-100008
    Figure PCTCN2019100198-appb-100008
  40. 如权利要求1-35任一项所述的制备方法或权利要求36所述的制备方法,化合物B可按照如下反应路线制得:According to the preparation method of any one of claims 1-35 or the preparation method of claim 36, compound B can be prepared according to the following reaction route:
    Figure PCTCN2019100198-appb-100009
    Figure PCTCN2019100198-appb-100009
PCT/CN2019/100198 2019-05-31 2019-08-12 Preparation method for 4-idarubicin hydrochloride WO2020237836A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910466305.4 2019-05-31
CN201910466305.4A CN112010913B (en) 2019-05-31 2019-05-31 Preparation method of 4-deoxy daunorubicin

Publications (1)

Publication Number Publication Date
WO2020237836A1 true WO2020237836A1 (en) 2020-12-03

Family

ID=73500549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/100198 WO2020237836A1 (en) 2019-05-31 2019-08-12 Preparation method for 4-idarubicin hydrochloride

Country Status (2)

Country Link
CN (1) CN112010913B (en)
WO (1) WO2020237836A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115785168B (en) * 2022-08-22 2023-11-07 浙江亚瑟医药有限公司 Method for preparing 4-demethoxydaunorubicin hydrochloride

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028667A1 (en) * 2008-09-11 2010-03-18 W.C. Heraeus Gmbh Genetically modified strains for biotransformations in anthracycline production
US8846882B2 (en) * 2011-04-29 2014-09-30 Synbias Pharma Ag Method of producing 4-demethoxydaunorubicin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1262565B (en) * 1993-09-30 1996-07-04 Menarini Farma Ind ANTHRACYCLINE DISACCARIDES, THEIR PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP2233465B1 (en) * 2008-01-10 2017-06-28 Shanghai Institute of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
CN101993446B (en) * 2009-08-13 2012-11-28 中国科学院上海药物研究所 Novel benzanthracene cyclic compounds and preparation method and use thereof
CN102336704B (en) * 2011-10-19 2013-04-17 丁克 Method for preparing Roflumilast
CN108003118A (en) * 2017-12-27 2018-05-08 张家口市格瑞高新技术有限公司 A kind of posaconazole intermediate 1-(4- hydroxy phenyls)-4-(4- aminophenyls)The preparation process of-piperazine
CN108658730A (en) * 2018-05-11 2018-10-16 常州大学 A kind of preparation method of p-fluorophenol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028667A1 (en) * 2008-09-11 2010-03-18 W.C. Heraeus Gmbh Genetically modified strains for biotransformations in anthracycline production
US8846882B2 (en) * 2011-04-29 2014-09-30 Synbias Pharma Ag Method of producing 4-demethoxydaunorubicin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PU, GANG ET AL.: "Semisynthesis of Idarubicin", CHINESE JOURNAL OF ANTIBIOTICS, no. 03, 30 April 2006 (2006-04-30), DOI: 8980301 *

Also Published As

Publication number Publication date
CN112010913A (en) 2020-12-01
CN112010913B (en) 2022-06-21

Similar Documents

Publication Publication Date Title
WO2017084401A1 (en) Sugammadex preparation and purification method
EP2794633A2 (en) Synthesis of abiraterone and related compounds
CN104447934B (en) A kind of purification process of Abiraterone acetate
TW201704234A (en) Crystals of azabicyclic compound
CN108047265A (en) A kind of everolimus intermediate prepares purification process
CN107325082B (en) Preparation method of high-purity afatinib
WO2020237836A1 (en) Preparation method for 4-idarubicin hydrochloride
US20140011992A1 (en) Synthesis of abiraterone and related compounds
CN109134500A (en) A kind of 1/2 water cefradine compound
CN109096306A (en) A kind of 1/2 water Cefazolin sodium compound
CN111253392B (en) Method for preparing apixaban
JPH03240794A (en) Crystal of 2'-deoxy-2'-methylidenecytidine dihydrate
CN109678701B (en) Preparation method of vilanterol intermediate
CN105753732A (en) Crystal form of AHU377 as well as preparation method and application thereof
WO2016124125A1 (en) New crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride
CN113603813A (en) Impurity of diphenyl phosphate derivative as sugammadex sodium intermediate and preparation method thereof
CN112724110A (en) Synthesis method of VEGFR inhibitor furoquintinib and benzofuran intermediate thereof
CN110759848A (en) Ethanesulfonic acid nintedanib impurity as well as preparation method and application thereof
CN112898277B (en) Preparation method of afatinib intermediate
CN114163380B (en) Alvacpam intermediate and preparation method and application thereof
CN111574448B (en) Preparation method of phenyl tetrahydroisoquinoline
CN115785048B (en) GL-V9 crystal form and preparation method thereof
CN109293613B (en) Epidaunorubicin intermediate compound
CN114057684B (en) Synthesis method of tiotropium bromide intermediate methyl bis (2-dithienyl) glycolate
WO2018233273A1 (en) Industrial preparation method for high-purity dicycloplatin needle-like crystal

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19930222

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19930222

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 19930222

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 27/06/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 19930222

Country of ref document: EP

Kind code of ref document: A1